GEOGRAPHIC ATROPHY (GA)
Clinical trials for GEOGRAPHIC ATROPHY (GA) explained in plain language.
Never miss a new study
Get alerted when new GEOGRAPHIC ATROPHY (GA) trials appear
Sign up with your email to follow new studies for GEOGRAPHIC ATROPHY (GA), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Race to slow blinding eye disease in major drug trial
Disease control Recruiting nowThis study is testing two investigational drugs, pozelimab and cemdisiran, to see if they can slow down the progression of geographic atrophy, a late-stage form of age-related macular degeneration that causes permanent central vision loss. The trial will involve about 975 partici…
Matched conditions: GEOGRAPHIC ATROPHY (GA)
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
First human test of new eye drug for blinding condition
Disease control Recruiting nowThis is an early-stage study testing the safety of an experimental drug called pozelimab, given as an injection into the eye. It involves about 54 people with geographic atrophy, a condition that causes progressive vision loss. The main goal is to see how well people tolerate the…
Matched conditions: GEOGRAPHIC ATROPHY (GA)
Phase: PHASE1 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
New eye injection aims to halt leading cause of blindness
Disease control Recruiting nowThis study is testing whether an experimental eye injection called ONL1204 can slow the progression of geographic atrophy, a severe form of age-related macular degeneration that causes permanent vision loss. Researchers will compare different doses and schedules of the injection …
Matched conditions: GEOGRAPHIC ATROPHY (GA)
Phase: PHASE2 • Sponsor: ONL Therapeutics • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC